Navigation Links
Unigene Reports Third Quarter 2011 Financial Results
Date:11/9/2011

160;Under the terms of the agreement, Unigene will receive up to approximately $2.2 million in payments from GSK to undertake certain development and manufacturing activities related to the active pharmaceutical ingredient and finished drug product of an oral formulation of a recombinantly produced investigational PTH analog for the treatment of osteoporosis in postmenopausal women in advance of GSK's potential decision to study the molecule in a Phase 3 study.  

On October 20, 2011, the Company announced that all dosing has been completed with the Phase 2 study.  Based on a review of the Phase 2 data, GSK may elect to assume responsibility for all future development and commercialization of the product.

Oral Calcitonin Program with Tarsa TherapeuticsIn 2009, Unigene licensed its late-stage oral calcitonin formulation to Tarsa Therapeutics (Tarsa), a venture financed company founded exclusively to conduct Phase 3 clinical testing and prepare Unigene's proprietary oral calcitonin formulation for commercialization. Unigene owns a 20% equity position in Tarsa on a fully diluted basis, subject to liquidating preferences. The Company is also eligible to receive sales-related milestone payments and royalties on worldwide sales excluding China.  

On September 19, 2011, Unigene announced that Tarsa presented positive Phase 3 data from its ORACAL trial of OSTORA™ during the annual American Society for Bone and Mineral Research (ASBMR) 2011 meeting. The data demonstrated that OSTORA achieved all of the efficacy endpoints in the trial, indicated that the safety profile of OSTORA did not substantially differ from nasal calcitonin or placebo and that OSTORA also appeared to be significantly less immunogenic than nasal calcitonin spray.  Developed by Unigene and licensed to Tarsa, OSTORA™ is an oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

The
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
2. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. GenVec Reports Third Quarter 2011 Financial Results
5. Chindex International, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. Allied Healthcare Products Reports First Quarter Loss on Sales Decline
7. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
8. Stereotaxis Reports Third Quarter Financial Results
9. Isis Reports Financial Results and Highlights for Third Quarter 2011
10. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
11. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... KALAMAZOO, Mich. , June 29, 2015 /PRNewswire/ ... Association and American Stroke Association give hope for ... patients who experience an acute ischemic stroke each ... of the key products used in the clinical ... The new AHA/ASA guidelines strongly recommend endovascular ...
(Date:6/29/2015)... , June 29, 2015 ... positive preliminary results from its BVX-006 Phase II clinical ... vaccine. In this trial, M-001 was injected intramuscularly to ... by an administration of the 2014/15 season trivalent influenza ... be safe and well tolerated and induced humoral immune ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
Breaking Medicine Technology:New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3
... JERUSALEM, Oct. 13, 2011 IDenta Corp. (OTC: IDTA) CEO ... Shoham stated, "We are succeeding in making sales in many ... products. We have received an order for 2000 ... http://www.gksolutions.com.au/ In the past several ...
... Association for Homecare urges the Joint Select Committee on ... cuts that will restrict access to home medical ... Over the years, homecare has broadened health care access ... the health care system by keeping seniors and people ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2American Association for Homecare Calls on Joint Deficit Committee in Congress to Preserve Homecare Access for Millions of Americans 2
(Date:6/29/2015)... Milwaukee, Wisconsin (PRWEB) , ... June 29, 2015 ... ... thrilled with the news that the European Medicines Agency (EMA) has granted accelerated ... , “Melanoma remains a global public health threat and the approval of nivolumab ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... products, announces the Fresh Plus Diaper, a baby invention that makes parenthood less ... is projected to reach a market value of USD 52.2 billion in 2017," ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... filed against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in ... Case Management Conference is to be convened on Thursday, July 23rd at 12:00 ...
(Date:6/29/2015)... ... 2015 , ... OR Manager announced Monday the launch of an enhanced ... a redesigned logo and weekly eLetter. The website contains the same informational articles, products, ... to navigate. , In addition to a refreshed look, http://www.ormanager.com now ...
(Date:6/29/2015)... MI (PRWEB) , ... June 29, 2015 , ... Celebrities ... perfect ten and have flawless skin all summer long and beyond. People don’t ... simple steps to slow the aging process, maintain an even skin tone, avoid breakouts, ...
Breaking Medicine News(10 mins):Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:OR Manager Launches New Website 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3
... terms, anesthesia-associated mortality has risen again. The reasons for ... older and multimorbid patients and surgical procedures that would ... result of a selective literature review of Andr Gottschalk,s ... current issue of Deutsches rzteblatt International ( ...
... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
... News) -- New research links medical problems caused by blood ... storage. The findings suggest that a better way to store ... high amounts of blood can lead to complications, including infection, ... Mark T. Gladwin in a news release from Wake Forest ...
... (NNI) released four reports that are the result ... issues in the nanotechnology environmental, health, and safety ... part of an ongoing strategy to coordinate nanotechnology-related ... and the Federal Government to share the latest ...
... , THURSDAY, July 21 (HealthDay News) -- The ... exhaustion, increases with age, experts at the U.S. National Institute ... researchers explained, they are less able to adapt to high ... a result, the heat might exacerbate any medical conditions they ...
... July 20 (HealthDay News) -- In a long-awaited move, ... the blood thinner Brilinta (ticagrelor) for use in patients ... for heart attack and death. Acute coronary syndromes ... attack linked to lowered blood flow to the heart, ...
Cached Medicine News:Health News:Minority participants crucial to effective aging studies 2Health News:Blood Stored Too Long May Threaten Patient Safety 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:Elderly at Greater Risk for Heat Stroke, Experts Warn 2Health News:FDA Approves Blood Thinner Brilinta for Heart Patients 2
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: